JP2021511047A - 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス - Google Patents

無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス Download PDF

Info

Publication number
JP2021511047A
JP2021511047A JP2020539779A JP2020539779A JP2021511047A JP 2021511047 A JP2021511047 A JP 2021511047A JP 2020539779 A JP2020539779 A JP 2020539779A JP 2020539779 A JP2020539779 A JP 2020539779A JP 2021511047 A JP2021511047 A JP 2021511047A
Authority
JP
Japan
Prior art keywords
itr
sequence
sense
expression cassette
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511047A5 (cg-RX-API-DMAC7.html
Inventor
オザン アルカン,
オザン アルカン,
ロバート マイケル コーティン,
ロバート マイケル コーティン,
マシュー スタントン,
マシュー スタントン,
ダグラス アンソニー カー,
ダグラス アンソニー カー,
キャロライン ペレティエ,
キャロライン ペレティエ,
Original Assignee
ジェネレーション バイオ カンパニー
ジェネレーション バイオ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネレーション バイオ カンパニー, ジェネレーション バイオ カンパニー filed Critical ジェネレーション バイオ カンパニー
Publication of JP2021511047A publication Critical patent/JP2021511047A/ja
Publication of JP2021511047A5 publication Critical patent/JP2021511047A5/ja
Priority to JP2023116157A priority Critical patent/JP2023126487A/ja
Priority to JP2025084944A priority patent/JP2025113389A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/103—Plasmid DNA for invertebrates
    • C12N2800/105—Plasmid DNA for invertebrates for insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020539779A 2018-01-19 2019-01-18 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス Pending JP2021511047A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023116157A JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
JP2025084944A JP2025113389A (ja) 2018-01-19 2025-05-21 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619392P 2018-01-19 2018-01-19
US62/619,392 2018-01-19
PCT/US2019/014122 WO2019143885A1 (en) 2018-01-19 2019-01-18 Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116157A Division JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス

Publications (2)

Publication Number Publication Date
JP2021511047A true JP2021511047A (ja) 2021-05-06
JP2021511047A5 JP2021511047A5 (cg-RX-API-DMAC7.html) 2022-02-24

Family

ID=67301565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020539779A Pending JP2021511047A (ja) 2018-01-19 2019-01-18 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
JP2023116157A Withdrawn JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
JP2025084944A Pending JP2025113389A (ja) 2018-01-19 2025-05-21 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023116157A Withdrawn JP2023126487A (ja) 2018-01-19 2023-07-14 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
JP2025084944A Pending JP2025113389A (ja) 2018-01-19 2025-05-21 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス

Country Status (16)

Country Link
US (1) US12442015B2 (cg-RX-API-DMAC7.html)
EP (1) EP3740571A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021511047A (cg-RX-API-DMAC7.html)
KR (2) KR20250159738A (cg-RX-API-DMAC7.html)
CN (1) CN111868242A (cg-RX-API-DMAC7.html)
AU (1) AU2019210034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020013319A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088984A1 (cg-RX-API-DMAC7.html)
IL (1) IL275878B2 (cg-RX-API-DMAC7.html)
MA (1) MA51626A (cg-RX-API-DMAC7.html)
MX (1) MX2020005790A (cg-RX-API-DMAC7.html)
MY (1) MY208589A (cg-RX-API-DMAC7.html)
PH (1) PH12020550878A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202005271TA (cg-RX-API-DMAC7.html)
UA (1) UA130154C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019143885A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506771A (ja) * 2018-11-09 2022-01-17 ジェネレーション バイオ カンパニー 対称的な修飾型逆位末端反復配列を含む修飾型閉端dna(cedna)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
AU2019221642A1 (en) * 2018-02-14 2020-07-09 Generation Bio Co. Non-viral DNA vectors and uses thereof for antibody and fusion protein production
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
GB201905651D0 (en) 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
WO2021011842A1 (en) 2019-07-17 2021-01-21 Generation Bio Co. Synthetic production of single-stranded adeno associated viral dna vectors
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
IL296660A (en) * 2020-03-24 2022-11-01 Generation Bio Co Non-viral DNA vectors and their use for therapeutic expression of factor ix
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
US20220243201A1 (en) * 2020-08-23 2022-08-04 Bioverativ Therapeutics Inc. Engineered itr sequences and methods of use
MX2023003019A (es) * 2020-09-16 2023-05-08 Generation Bio Co Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah).
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
CA3209115A1 (en) * 2021-01-25 2022-07-28 Prevail Therapeutics, Inc. Modulation of aav-based gene expression
CN112980862A (zh) * 2021-02-25 2021-06-18 通用生物系统(安徽)有限公司 一种高纯度微环dna的制备方法
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
US20240216535A1 (en) * 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
JP2024515788A (ja) * 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスdnaベクター及びその使用
WO2022236016A1 (en) * 2021-05-07 2022-11-10 Generation Bio Co. Lyophilized non-viral dna vector compositions and uses thereof
EP4333886A4 (en) * 2021-05-07 2025-11-12 Generation Bio Co NON-VIRAL DNA VECTORS FOR VACCINE ADMINISTRATION
US20250049961A1 (en) * 2021-12-23 2025-02-13 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
US20260199386A1 (en) * 2022-12-01 2026-07-16 Generation Bio Co. Synthetic single-stranded dna molecules and methods of producing and using the same
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
US11993783B1 (en) * 2023-03-27 2024-05-28 Genecraft Inc. Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
WO2026085495A1 (en) 2024-10-18 2026-04-23 Generation Bio Co. Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046066A (ja) * 2007-08-10 2010-03-04 Toto Ltd 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
AU2002365514A1 (en) 2001-11-30 2003-06-10 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
US8709778B2 (en) * 2008-10-28 2014-04-29 Xavier Danthinne Method of adenoviral vector synthesis
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
EP2970966A4 (en) * 2013-03-15 2016-10-26 Univ North Carolina SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
WO2019101596A1 (en) 2017-11-21 2019-05-31 Expedeon Ltd Methods and kits for amplification of double stranded dna
AU2019221642A1 (en) 2018-02-14 2020-07-09 Generation Bio Co. Non-viral DNA vectors and uses thereof for antibody and fusion protein production
KR20210119416A (ko) * 2019-01-24 2021-10-05 제너레이션 바이오 컴퍼니 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
WO2021011842A1 (en) * 2019-07-17 2021-01-21 Generation Bio Co. Synthetic production of single-stranded adeno associated viral dna vectors
US20220228171A1 (en) * 2019-07-17 2022-07-21 Generation Bio Co. Compositions and production of nicked closed-ended dna vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046066A (ja) * 2007-08-10 2010-03-04 Toto Ltd 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENE THER. 2013, VOL.20, NO.6, PP.686-693, JPN6023006400, ISSN: 0005543988 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506771A (ja) * 2018-11-09 2022-01-17 ジェネレーション バイオ カンパニー 対称的な修飾型逆位末端反復配列を含む修飾型閉端dna(cedna)
JP7590963B2 (ja) 2018-11-09 2024-11-27 ジェネレーション バイオ カンパニー 対称的な修飾型逆位末端反復配列を含む修飾型閉端dna(cedna)

Also Published As

Publication number Publication date
CA3088984A1 (en) 2019-07-25
RU2020127017A (ru) 2022-02-21
AU2019210034A1 (en) 2020-07-09
IL275878B2 (en) 2026-03-01
KR102879598B1 (ko) 2025-11-03
EP3740571A4 (en) 2021-12-08
AU2019210034B2 (en) 2025-03-27
MA51626A (fr) 2020-11-25
SG11202005271TA (en) 2020-07-29
BR112020013319A2 (pt) 2020-12-01
US20210071197A1 (en) 2021-03-11
UA130154C2 (uk) 2025-12-03
IL275878A (en) 2020-08-31
US12442015B2 (en) 2025-10-14
IL275878B1 (en) 2025-11-01
PH12020550878A1 (en) 2021-04-05
KR20250159738A (ko) 2025-11-11
JP2025113389A (ja) 2025-08-01
JP2023126487A (ja) 2023-09-07
EP3740571A1 (en) 2020-11-25
KR20200111726A (ko) 2020-09-29
MY208589A (en) 2025-05-19
WO2019143885A1 (en) 2019-07-25
MX2020005790A (es) 2020-10-28
CN111868242A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
JP2023126487A (ja) 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
JP2022190081A (ja) 修飾型閉端dna(cedna)
JP7590963B2 (ja) 対称的な修飾型逆位末端反復配列を含む修飾型閉端dna(cedna)
JP2021505159A (ja) 修飾型閉端dna(cedna)を使用する遺伝子編集
JP2021513999A (ja) 閉端dna(cedna)ベクターを使用した導入遺伝子の制御された発現
JP7583732B2 (ja) フェニルアラニンヒドロキシラーゼ(pah)治療薬を発現するための非ウイルス性dnaベクターおよびその使用
JP2022520803A (ja) 閉端DNA(ceDNA)の産生におけるREPタンパク質活性の調節
AU2020315444A1 (en) Synthetic production of single-stranded adeno associated viral DNA vectors
AU2020314865A1 (en) Compositions and production of nicked closed-ended DNA vectors
JP2024511026A (ja) Pfic治療薬を発現させるための非ウイルス性dnaベクター及びその使用
JP2022523806A (ja) 閉端dna(cedna)および免疫調節化合物
JP2023520763A (ja) ゴーシェ治療薬を発現するための非ウイルス性dnaベクター及びその使用
CN116507730A (zh) 封闭端dna载体及其用于表达苯丙氨酸羟化酶(pah)的用途
US20250049961A1 (en) Scalable and high-purity cell-free synthesis of closed-ended dna vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241220